SCHEMBL851695

SCHEMBL851695

CC(C)(C)OC(=O)NCC(O)(c1ccc(Cl)cc1)c1ccc(I)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 7/20 0.49
GAA P10253 2/20 0.44
DRD2 P14416 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 7/20 0.40
HTT P42858 4/20 0.40
IDO1 P14902 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3800474 0.83 NPSR1 (0.45) NPSR1GAADRD2MEN1KMT2A
SCHEMBL26954735 0.79 NPSR1 (0.44) NPSR1GAADRD2MEN1KMT2A
SCHEMBL28323945 0.79 EPHX2 (0.41) NPSR1IDO1
SCHEMBL851496 0.79 ROCK2 (0.59) NPSR1
SCHEMBL2067960 0.79 IDO1 (0.46) GAAMEN1KMT2AIDO1CYP2C19
SCHEMBL26954805 0.78 NPSR1 (0.43) NPSR1GAADRD2MEN1KMT2A
SCHEMBL4752129 0.77 KDM4A (0.34) POLBLMNAIDO1
SCHEMBL9449675 0.76 GAA (0.44) NPSR1GAADRD2MEN1KMT2A
SCHEMBL26954826 0.76 NPSR1 (0.43) NPSR1GAADRD2MEN1KMT2A
SCHEMBL12157315 0.75 NPSR1 (0.57) NPSR1GAAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134339-B1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LTD (GB) 2014-09-17 EP disclosed
EP-2134339-B1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LTD (GB) 2014-09-17 EP disclosed
US-8497294-B2 Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases ASTEX THERAPEUTICS LIMITED (GB) 2013-07-30 US disclosed
US-8497294-B2 Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases ASTEX THERAPEUTICS LIMITED (GB) 2013-07-30 US disclosed
US-8497294-B2 Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases ASTEX THERAPEUTICS LIMITED (GB) 2013-07-30 US disclosed
EP-2433632-A1 Compositions and combinations comprising non-racemic 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, for use in medicine Astex Therapeutics Limited (GB) 2012-03-28 EP disclosed
US-20110269808-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LIMITED (GB) 2011-11-03 US disclosed
US-20110269808-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LIMITED (GB) 2011-11-03 US disclosed
US-20100113551-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-05-06 US disclosed
EP-2134339-A2 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES Astex Therapeutics Limited (GB) 2009-12-23 EP disclosed
WO-2008110846-A2 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES ASTEX THERAPEUTICS LIMITED (GB) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113551-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES MAP4K2, PRKCH, DSTYK NPSR1 3044/4885GAA 4761/4885DRD2 3293/4885
US-20110269808-A1 COMPOSITIONS COMPRISING (S)-2-AMINO-1-(4-CHLOROPHENYL)-1-[4-(1H-PYRAZOL-4-YL)-PHENYL]-ETHANOL AS MODULATOR OF PROTEIN KINASES MAP4K2, MAP4K1, PRKCH NPSR1 3259/4885GAA 4758/4885DRD2 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.